文献速递神经肌肉病

神经丝标志物与ALS上下运动神经元受累范围相关

Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease.
PubMed 文献 · Neurology · 2017-05-12

研究在220例ALS、316例神经疾病对照和50例真实疾病模仿者中评估脑脊液pNfH和NfL的诊断性能与预后价值。pNfH对运动神经元病特异性88.2%,鉴别ALS与模仿者敏感性90.7%、特异性88.0%。两者随上下运动神经元受累区域数增加而升高,但预后性能不佳。

要点

  • 脑脊液pNfH对ALS诊断具有附加价值,特异性88.2%。
  • pNfH鉴别ALS与疾病模仿者敏感性90.7%、特异性88.0%。
  • pNfH和NfL随上下运动神经元受累区域数增加而升高。

核心结论

  • 脑脊液pNfH浓度作为ALS诊断生物标志物具有附加价值。
  • pNfH和NfL均与运动神经元变性范围相关。
  • pNfH和NfL的预后价值有待进一步研究。

研究设计与样本

  • 研究纳入220例ALS患者、316例神经疾病对照和50例真实疾病模仿者。
  • 测量脑脊液pNfH和NfL浓度,确定诊断截断值并评估准确性。
  • 分析标志物与其他临床参数的相关性。

主要发现

  • pNfH对运动神经元病特异性88.2%(CI 83.0%-92.3%)。
  • pNfH鉴别ALS与疾病模仿者敏感性90.7%(CI 84.9%-94.8%)、特异性88.0%(CI 75.7%-95.5%)、似然比7.6(CI 3.6-16.0),截断值768 pg/mL。
  • 疾病进展缓慢者脑脊液pNfH和NfL水平显著较低,但对疾病进展率的预后性能不佳。
  • 脑脊液pNfH和NfL水平随上下运动神经元同时受累区域数增加而显著升高。

关键数值与推荐

  • pNfH诊断截断值为768 pg/mL。
  • 该截断值下鉴别ALS与疾病模仿者的敏感性90.7%、特异性88.0%、似然比7.6。
  • pNfH对运动神经元病特异性88.2%。

临床怎么用

  • 脑脊液pNfH可作为ALS诊断阶段的辅助生物标志物。
  • pNfH和NfL水平可反映运动神经元变性范围。
  • 不推荐单独依据pNfH或NfL判断疾病进展速度。

局限性

  • pNfH和NfL对疾病进展率的预后性能不佳。
  • pNfH和NfL的预后价值仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the diagnostic performance and prognostic value of phosphorylated neurofilament heavy chain (pNfH) and neurofilament light chain (NfL) in CSF as possible biomarkers for amyotrophic lateral sclerosis (ALS) at the diagnostic phase. METHODS: We measured CSF pNfH and NfL concentrations in 220 patients with ALS, 316 neurologic disease controls (DC), and 50 genuine disease mimics (DM) to determine and assess the accuracy of the diagnostic cutoff value for pNfH and NfL and to correlate with other clinical parameters. RESULTS: pNfH was most specific for motor neuron disease (specificity 88.2% [confidence interval (CI) 83.0%-92.3%]). pNfH had the best performance to differentially diagnose patients with ALS from DM with a sensitivity of 90.7% (CI 84.9%-94.8%), a specificity of 88.0% (CI 75.7%-95.5%) and a likelihood ratio of 7.6 (CI 3.6-16.0) at a cutoff of 768 pg/mL. CSF pNfH and NfL levels were significantly lower in slow disease progressors, however, with a poor prognostic performance with respect to the disease progression rate. CSF pNfH and NfL levels increased significantly as function of the number of regions with both upper and lower motor involvement. CONCLUSIONS: In particular, CSF pNfH concentrations show an added value as diagnostic biomarkers for ALS, whereas the prognostic value of pNfH and NfL warrants further investigation. Both pNfH and NfL correlated with the extent of motor neuron degeneration. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that elevated concentrations of CSF pNfH and NfL can accurately identify patients with ALS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017. PMID: 28500227. doi:10.1212/WNL.0000000000004029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。